论文部分内容阅读
DCCT、UKPDS及Steno-2研究的后续随访均发现,原强化治疗组在减少微血管病变和大血管病变风险方面持续获益,提示早期强化血糖控制使糖尿病患者获益最大。另一方面,ACCORD研究显示,在高危的2型糖尿病患者中,强化降糖治疗使全因死亡风险增高。因此,血糖控制的目标值应个体化,不但要重视强化降糖,更要保证降糖过程中不出现低血糖反应。
Subsequent follow-up of the DCCT, UKPDS and Steno-2 studies found that the former intensive treatment group continued to benefit in reducing the risk of microvascular disease and macrovascular disease, suggesting that early intensive glycemic control may benefit diabetic patients the most. On the other hand, the ACCORD study shows that in patients with high-risk type 2 diabetes, intensive hypoglycemic treatment increases the risk of all-cause mortality. Therefore, the target value of glycemic control should be individualized, not only to strengthen the emphasis on hypoglycemic, but also to ensure that hypoglycemic process does not appear hypoglycemic response.